Enanta Pharmaceuticals SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 28, 2026, 7:14 a.m. ETView on SEC.gov
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedEnanta Pharmaceuticals Announces Planned Retirement of CEO Jay R. Luly by February 1, 2027 and Names Tara L. Kieffer Chief Operating Officer
SCHEDULE 13GOct. 27, 2026, 4:09 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 8:26 a.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 8:19 a.m. ETView on SEC.gov
10-QAug. 12, 2026, 7 a.m. ETView on SEC.gov
4Aug. 10, 2026, 9 a.m. ETView on SEC.gov
8-KAug. 10, 2026, 4:05 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits